Maraviroc: Clinical Trials

(asked on 2nd July 2019) - View Source

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what estimate he has made of the cost to the NHS of clinical trials of Maraviroc in each of the last three years.


Answered by
Caroline Dinenage Portrait
Caroline Dinenage
This question was answered on 10th July 2019

In the last three years, four investigator initiated non-commercial clinical trials have been supported by the National Institute for Health Research Clinical Research Network (NIHR CRN).

The cost to the National Health Service of these clinical trials is limited to:

- NHS Treatment Costs - the patient care costs, which would continue to be incurred if the patient care service in question continued to be provided after the research and development study had stopped.

- Excess Treatment Costs (ETCs) –that result from giving patients new treatments or changing the way that care is delivered, if applicable for non-commercial research and development studies.

We do not hold information on what, if any ETCs have been incurred historically by the NHS for individual clinical trials.

As is standard practice for non-commercial research studies, the NIHR CRN provided NHS Support Costs to cover additional patient care costs associated with the research. Research Costs for the clinical trials were met by the research funders.

Reticulating Splines